About Dong M. Shin
Pleural and Lung Cancer
Excellence in Research
Board Certified in Medical Oncology
Board Certified in Internal Medicine
A native of South Korea, Dr. Dong Moon Shin completed his medical training at the Yonsei University College of Medicine in Seoul, receiving his medical degree in 1975. He then served a four-year internship at Yonsei University Hospital and another four-year internship at Cook County Hospital in Chicago.
He completed his residency at Cook County in 1985 and followed that with a Fellowship in Hematology and Medical Oncology at the University of Texas, M.D. Anderson Cancer Center, in Houston, in 1988. He joined the faculty of the Winship Cancer Institute in 2003, after 15 years as a faculty member at the M.D. Anderson Center and the University of Pittsburgh.
Shin is the recipient of numerous awards, grants, and professional recognitions. He has published more than 150 peer-reviewed articles in prestigious medical journals, such as the Journal of the National Cancer Institute and The New England Journal of Medicine. His research is cited in hundreds of studies and articles. Shin is certified in Internal Medicine and Medical Oncology by the American Board of Internal Medicine. He is a member of the American Association for Cancer Research and is a Fellow of the American College of Physicians and the American Society of Head and Neck Surgery.
Focused on Pleural Mesothelioma Research
He has done extensive research in:
- Establishing carcinogenesis models in preclinical and clinical settings
- Developing biomarkers in animal and human carcinogenesis for head, neck and lung cancer
- Developing novel therapeutics and protocols for rarer cancers like mesothelioma and thymoma (cancer of the thymus gland)
- The use of nanotechnology to deliver drugs to cancer patients
In 2003, a study conducted by Shin and others found positive results by treating pleural mesothelioma patients with a combination of chemotherapy and vitamin supplementation. Patients who received the drug, Pemetrexed with folic acid and vitamin B12 survived an average of five months longer than those who received Pemetrexed only.
Talk to a Doctor About Your Diagnosis
We can help you or a loved one get in contact with Dr. Shin and find the treatment that's best for you.Get Started Today
In 2005, Shin began a phase III clinical trial of Vorinostat (suberoylanilide hydromaxic acid) for patients with advanced malignant pleural mesothelioma that has gotten worse despite having at least one type of chemotherapy. Vorinostat is believed to help stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The drug is marketed by Merck Pharmaceuticals as Zolinza, and is currently FDA-approved for the treatment of cutaneous T-cell lymphoma. The study was completed in November 2011, but no results are posted yet.See More Top Mesothelioma Doctors
Dr. Shin’s Publications
Disclaimer: Dr. Dong M. Shin has no professional affiliation with Asbestos.com.
6 Cited Article Sources
The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.
- U.S. National Institutes of Health. (2012, April 3). Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1). Retrieved from: http://clinicaltrials.gov/show/NCT00128102
- Emory Winship Cancer Center. (n.d.). Dong M. Shin, MD, FACP. Retrieved August 24, 2012, from Retrieved from: http://winshipcancer.emory.edu/find-a-physician/WinshipContentPage.aspx?nd=807&id=221&typ=33
- Emory University - Woodruff Health Sciences Center. (2005, December 22) Emory Winship Cancer Institute to Conduct Phase III Clinical Trial on Pleural Mesothelioma. Retrieved from: http://whsc.emory.edu/press_releases2.cfm?announcement_id_seq=5421
- Emory University - Woodruff Health Sciences Center. (2005, December 22) Dong M. Shin, MD, Appointed to Associate Director of Emory Winship Cancer. Retrieved from: http://whsc.emory.edu/press_releases2.cfm?announcement_id_seq=5420
- Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma. (2003, April 15). Journal of Clinical Oncology. Retrieved from: http://jco.ascopubs.org/content/21/8/1556.full
- Dong M. Shin, MD, FACP. (n.d.). Retrieved August 23, 2012, from Retrieved from: https://winshipcancer.emory.edu/bios/faculty/shin-dong-moon.html
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?
Share this article
Last Modified December 5, 2019